Fasinumab is a human monoclonal antibody designed for the treatment of acute sciatic pain.[1][2]
This drug was developed in collaboration by Teva Pharmaceutical Industries and Regeneron Pharmaceuticals.
It is currently at Phase III trials (NCT03245008, NCT02683239, and NCT03161093).[3]
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.
Lokasi Pengunjung: 3.17.78.254